Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
About Pluri Inc. (Nasdaq: PLUR)
Pluri Inc. is a biotechnology company pioneering innovative, cell-based solutions to address global challenges in medicine, food production, and agriculture. Leveraging its proprietary three-dimensional (3D) cell expansion platform, Pluri transforms cells into scalable, high-quality products designed to promote global wellbeing and sustainability. The company’s cutting-edge technology enables mass production of cell-based products with unmatched consistency, scalability, and cost efficiency, positioning it as a leader in the biotechnology and cellular agriculture sectors.
Core Technology and Capabilities
At the heart of Pluri’s operations is its patented 3D cell expansion platform. This state-of-the-art system mimics natural cellular environments, allowing for the efficient cultivation of various cell types at industrial scales. The platform is fully automated, highly controlled, and validated for Good Manufacturing Practice (GMP) compliance, ensuring batch-to-batch consistency and regulatory readiness. Pluri’s technology has been successfully applied across multiple domains, including regenerative medicine, foodtech, and agricultural technology (agtech).
Business Segments
- Regenerative Medicine: Pluri develops cell-based therapies for conditions such as inflammation, ischemia, and hematological disorders. Its placental expanded (PLX) cells, derived from human placenta, are designed to stimulate the body’s natural healing processes without the need for tissue or genetic matching. These therapies address critical medical needs, including acute radiation syndrome (H-ARS) and neurodegenerative diseases.
- Foodtech: Through its subsidiary, Ever After Foods, Pluri applies its cell-expansion technology to cultivated meat production. This platform enables the creation of slaughter-free, sustainable meat products with superior taste, texture, and nutritional value. By reducing production costs and increasing scalability, Pluri is driving the commercialization of ethical, cultivated food solutions.
- Agricultural Technology (Agtech): Pluri collaborates with industry leaders to develop cell-based agricultural products aimed at improving food security and sustainability. These initiatives focus on reducing environmental impact and creating scalable alternatives to traditional farming methods.
- Contract Development and Manufacturing Organization (CDMO): Pluri offers its advanced manufacturing expertise to life science companies, providing end-to-end solutions from preclinical development to commercial-scale production. This includes partnerships to produce cell therapies for conditions like ALS and diabetes.
Market Position and Competitive Edge
Pluri operates in highly competitive markets, including cell therapy, cultivated food, and sustainable agriculture. Its key differentiator is its proprietary 3D cell expansion technology, which enables scalable, cost-effective production of cell-based products. The company’s ability to serve diverse industries while maintaining regulatory compliance and production efficiency positions it as a versatile and reliable partner. Strategic collaborations further enhance its market presence, as seen in partnerships with global leaders in foodtech, biotechnology, and agriculture.
Strategic Collaborations
Pluri has established partnerships with renowned organizations to accelerate innovation and commercialization. Notable collaborations include its work with Wilk Technologies to develop cell-based medical foods, its joint venture with Tnuva in cultivated meat, and its CDMO agreements with companies like Kadimastem and BrainStorm Cell Therapeutics. These alliances leverage Pluri’s technological expertise to address unmet needs across industries.
Commitment to Sustainability
Pluri’s mission extends beyond technological innovation to include a strong commitment to sustainability. By providing scalable alternatives to traditional methods in medicine, food production, and agriculture, the company aims to reduce environmental impact, promote ethical practices, and improve global food security.
Conclusion
Pluri Inc. stands at the forefront of the biotechnology revolution, offering transformative solutions that span regenerative medicine, foodtech, and agtech. Its proprietary 3D cell expansion platform is a cornerstone of its success, enabling the scalable production of high-quality, cell-based products. Through strategic collaborations and a commitment to sustainability, Pluri is well-positioned to address critical global challenges and drive innovation across multiple industries.
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) has signed a tech transfer and manufacturing agreement with Kadimastem (TASE: KDST) through its PluriCDMO™ division. PluriCDMO™ will manufacture two cell therapy product candidates for Kadimastem: AstroRx® for ALS treatment and IsletRx for diabetes treatment. This collaboration leverages Pluri's 47,000 square foot GMP cell production facility and expertise in developing and manufacturing cell-based products. The agreement supports Kadimastem's preparation for clinical trials and expansion into the U.S. market, particularly for an upcoming FDA Phase 2a study of AstroRx®. This partnership highlights PluriCDMO™'s versatility and commitment to advancing innovative life-saving therapies.
Pluri has entered a €1 million proof of concept (POC) agreement with an international agriculture The collaboration aims to boost global vegetable supply, shorten supply chains, and promote sustainable agriculture. Pluri’s 3D cell expansion technology and the partner's market expertise will work together to minimize environmental impact and enhance food security. This initiative aligns with Pluri's strategy to partner with global companies and generate revenue through innovative projects. The global vegetable farming market, valued at $1.3 trillion, is projected to grow to $1.6 trillion by 2029, driven by a rising global population.
Pluri's subsidiary, Ever After Foods, has secured $10 million in strategic investments from U.S. and EU investors, including Tnuva Group. This funding aims to tackle scalability challenges in cultivated food production. Ever After Foods' innovative platform can produce cultivated meat, fish, and seafood with significant cost-efficiency, reducing production costs by over 90% and increasing protein and lipid yields substantially.
Leveraging Pluri's technology, Ever After Foods aims to expand its global market presence. The technology enables natural production of muscle and fat tissues, ensuring taste and texture akin to conventional meat. The new funding will also broaden Ever After Foods' scope to include cultivated fish, reinforcing its position as a leading technology enabler in the food industry.
Pluri announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has exercised a $1.4 million second-year funding option for a contract to develop PLX-R18, a cell therapy for Acute Radiation Syndrome (H-ARS). The contract, part of a $4.2 million three-year agreement, supports manufacturing, in vitro, and in vivo studies for PLX-R18. The therapy aims to counteract hematopoietic complications from ionizing radiation. Significant survival rate increases in both animal and human studies have been reported. PLX-R18 has also received FDA Orphan Drug Designation.
Pluri (Nasdaq: PLUR) has announced a strategic partnership with Wilk Technologies to create a medical food product derived from human breast milk for the elderly. This innovative product utilizes Pluri's 3D cell-expansion technology in combination with Wilk's cell-cultured milk components. The global elderly nutrition market, valued at $25.2 billion, is projected to reach $39.7 billion within the next decade. This collaboration aims to meet the unique nutritional needs of seniors, enhancing their quality of life while addressing age-related health concerns and chronic illnesses.
Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 billion by 2032. Renowned cancer researchers Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall joined Pluri's Scientific Advisory Board to support this groundbreaking platform.
FAQ
What is the current stock price of Pluri (PLUR)?
What is the market cap of Pluri (PLUR)?
What is Pluri Inc.'s core technology?
What industries does Pluri Inc. operate in?
How does Pluri differentiate itself from competitors?
What are Pluri’s key business segments?
What are some examples of Pluri’s strategic collaborations?
What is the significance of Pluri’s PLX cells?
How does Pluri contribute to sustainability?
What is Pluri’s role in the cultivated meat industry?
What is PluriCDMO?
What are the applications of Pluri’s 3D cell expansion platform?
